摘要
目的评价沙利度胺联合介入治疗中晚期肝癌的临床疗效。方法89例中晚期肝癌患者随机分为口服沙利度胺+肝动脉灌注栓塞化疗组(TLD+TACE组)和单纯肝动脉灌注栓塞化疗组(TACE组)。结果TLD+TACE组近期有效率、1年局控率分别为57.5%和65.0%,明显高于TA-CE组的34.5%和43.1%。不良反应以腹胀、便秘、头晕、嗜睡最常见,患者可耐受。结论沙利度胺联合介入治疗中晚期肝癌疗效明显,不良反应轻,具有一定的临床应用价值。
Objective To evaluate the clinical efficacy of thalidomide combined with interventional therapy in treatment of advanced hepatocellular carcinoma. Methods Eighty-nine patients with advanced hepatocellular carcinoma were divided randomly into two groups：thalidomide（TLD） ＋ transcatheter arterial chemoembolization （TACE） group and TACE group. Results The immediate effective rate and one year partial control rate of TLD ＋ TACE group were 57.5% and 65.0% respectively,while those of the TACE group were 34.5% and 43.1% respectively. Thalidomide could cause abdominal distention, constipation, vertigo and somnolence,which could be tolerated by the patients. Conclusions Combined thalidomide and interventional therapy is more effective than TACE alone for the advanced hepatocellular carcinoma. Its adverse effects are tolerable, so it has certain value for clinical application.
出处
《中国肿瘤临床与康复》
2007年第6期546-547,550,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
关键词
肝肿瘤
沙利度胺
介入治疗
Liver neoplasms
Thalidomide
Interventional therapy
